APLS Apellis Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: APLS

Price (delayed)

$46.07

Market cap

$3.7B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.59

Enterprise value

$3.51B

Sector: Healthcare
Industry: Biotechnology
Website: http://apellis.com/

Highlights

The equity has surged by 93% since the previous quarter
The EPS is up by 41% since the previous quarter and by 6% year-on-year
APLS's net income is up by 36% since the previous quarter but it is down by 13% year-on-year
The company's quick ratio fell by 29% QoQ but it rose by 28% YoY
The company's debt has surged by 141% YoY

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
80.38M
Market cap
$3.7B
Enterprise value
$3.51B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.06
Price to sales (P/S)
13.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.02
Earnings
Revenue
$250.65M
EBIT
-$313.09M
EBITDA
-$312.23M
Free cash flow
-$165.91M
Per share
EPS
-$4.59
Free cash flow per share
-$2.21
Book value per share
$2.7
Revenue per share
$3.33
TBVPS
$12.78
Balance sheet
Total assets
$960.57M
Total liabilities
$756.01M
Debt
$377.73M
Equity
$204.56M
Working capital
$788.87M
Liquidity
Debt to equity
1.85
Current ratio
7.15
Quick ratio
6.85
Net debt/EBITDA
0.61
Margins
EBITDA margin
-124.6%
Gross margin
100%
Net margin
-137.6%
Operating margin
-85.3%
Efficiency
Return on assets
-42%
Return on equity
-172.1%
Return on invested capital
-49.6%
Return on capital employed
-37.6%
Return on sales
-124.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
0%
1 week
1.1%
1 month
9.85%
1 year
29.81%
YTD
-19.46%
QTD
7.36%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$250.65M
Gross profit
$250.65M
Operating income
-$213.73M
Net income
-$344.87M
Gross margin
100%
Net margin
-137.6%
APLS's operating margin has surged by 100% since the previous quarter
The company's net margin has surged by 100% QoQ
APLS's operating income has surged by 52% since the previous quarter and by 26% year-on-year
APLS's net income is up by 36% since the previous quarter but it is down by 13% year-on-year

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.06
P/S
13.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.02
The EPS is up by 41% since the previous quarter and by 6% year-on-year
The equity has surged by 93% since the previous quarter
The P/B is 12% more than the last 4 quarters average of 15.3

Efficiency

How efficient is Apellis Pharmaceuticals business performance
The return on sales has surged by 100% since the previous quarter
The company's return on invested capital has surged by 88% YoY and by 51% QoQ
APLS's ROE is up by 49% QoQ and by 21% YoY
APLS's ROA is up by 49% year-on-year and by 47% since the previous quarter

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 27% more than its total liabilities
Apellis Pharmaceuticals's total assets has soared by 147% YoY and by 25% from the previous quarter
APLS's total liabilities has surged by 113% year-on-year and by 14% since the previous quarter
The company's debt is 85% higher than its equity
The company's debt has surged by 141% YoY
The equity has surged by 93% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.